Reflections on the 14th World Conference on Lung Cancer: A European Perspective-Reference-Cited by-同舟云学术

Reflections on the 14th World Conference on Lung Cancer: A European Perspective

Published:2012-02-21 Issue:3 Volume:17 Page:463-465
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Senan Suresh¹,Postmus Pieter E.²

Affiliation:

1. a Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands

2. b Department of Pulmonology, VU University Medical Center, Amsterdam, The Netherlands

Abstract

Observations from the 14th World Conference on Lung Cancer, held in Amsterdam July 3–7, 2011, are presented.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://pericles-gcp.literatumonline.com/doi/pdf/10.1634/theoncologist.2011-0309

Reference13 articles.

1. Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop;Bover;Lung Cancer,2011

2. O10.01: The EURTAC (European Tarceva® vs Chemotherapy) study: Interim results of a phase III randomized trial of erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutations;Gervais;J Thorac Oncol,2011

3. PRS. 5: In vivo selection of non-small cell lung cancer patients with activating mutations in the tumor epidermal growth factor receptor using [11C] erlotinib and positron emission tomography;Bahce;J Thorac Oncol,2011

4. O01.06: Epidermal growth factor receptor (EGFR) expression as a predictor of survival for first-line chemotherapy plus cetuximab in flex study patients with advanced non-small cell lung cancer;Pirker;J Thorac Oncol,2011

5. O31.06: Crizotinib improves overall survival of ALK-positive patients with advanced NSCLC compared with historical controls;Shaw;J Thorac Oncol,2011